A Prospective, Randomized, Open Label, Two arm, Comparative Clinical Study to Evaluate the effect of IMMUNODAATÃ¢â??Â¢ Botanical Ingredient, in Post Covid-19 recovery - NI

ODAAT PHARMA0 个研究点目标入组 74 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Patients who had mild to moderate symptoms [as per US-CDC classification) of COVID-19 (Ref: www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html) (Mild symptoms up to mild pneumonia) and is recovered clinically.
•2.Patients will be recruited from the day of clinical recovery till next 15 days and having Post Covid Symptoms as per https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects
•3.Ready to provide written informed consent for participation in the study
•4.Willing to follow COVID-19 (prevention and containment) related guidelines issued from time to time by Govt. / local health authority throughout the study period.

•1.Subjects who had severe COVID-19 (moderate to severe pneumonia)
•2.Subjects with post COVID 19 complications (those who had gone into severe type of COVID-19)
•3.Chronic, Severe, Unstable, Uncontrolled co-existent medical illness such as, Hypertension, Cardiac disorders, liver, kidney disorders and lung disorders or other disease of concern which may put the patient at increased risk during the study
•4.Being pregnant or breastfeeding, or having a positive pregnancy test at the time of pre-dose inspection, or planning to become pregnant within 3 months of study treatment.
•5.Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening
•6.Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis and Cancer etc.
•7.Subjects taking steroid treatment and or any kind of immunosuppressive therapy prior to participation in the study
•8.Allergies, known to be allergic to IMMUNODAATÃ¢â??Â¢ Botanical Ingredient
•9.Any other conditions which in the opinion of investigator will place the subject at risk or will influence the conduct of study or interpretation of results

发起方

ODAAT PHARMA